Inclusion Criteria:  Men and women between age 18-80 years who are diagnosed with stones who undergo ureteroscopy and ureteral stent placement. Patients who consent to the procedure will be randomized in 1:1 fashion by RedCAP either to the methocarbamol or oxybutynin arm. All patients will receive standard of care diclofenac, tamsulosin, and pyridium for pain control plus one of the study drugs. Willing to take only diclofenac (or tramadol for patients with contraindication to diclofenac), phenazopyridine, and acetaminophen for post stent placement discomfort. Willing to sign the Informed Consent Form. Able to read, understand, and complete patient questionnaires, pain texts, and medication diary.  Exclusion Criteria:  Active, symptomatic urinary tract infection. Non-stone related ureteral obstruction or stricture. Procedural trauma or significant retained stone burden that could significantly contribute to patient discomfort. Spinal cord injuries (sensory loss due to injury). Non-stone related voiding dysfunction requiring supplemental bladder drainage tubes for more than 24 hours post operatively. Chronic opioid usage for pain. Members of vulnerable patient populations.